Chemical compound
 ;templatestyles src="Infobox drug/styles.css"/ ;
Galunisertib (LY2157299) is a small molecular experimental cancer drug previously in development by Eli Lilly. It is a TGF-b inhibitor. Development of galunisertib by Eli Lilly was discontinued in January 2020.
Galunisertib was investigated in a phase II trial for treatment of hepatocellular carcinoma. Pre-clinically, combination of galunisertib with PD-L1 blockade resulted in improved tumor growth inhibition.
References.
 ;templatestyles src="Reflist/styles.css" / ;